Market Intelligence, Clinical Progress, and High-Purity Reagents for Eosinophil Peroxidase-Targeted Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EPX drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPX Recombinant Protein HEK293 expressed, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View EPX Products |
| Gene Delivery | EPX Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View EPX Products |
| Benchmark Ab | Anti-EPX Recombinant Antibody Recombinant positive control matching clinical/academic benchmark sequences. |
View EPX Products |
| Validator | EPX siRNA Set Target-specific knockdown verification in primary eosinophils or cell lines. |
View EPX Products |
| Related Target A | IL5 Key cytokine driving eosinophil differentiation, survival, and EPX release. |
View IL5 Products |
| Related Target B | CCR3 Chemokine receptor mediating eosinophil homing to inflammatory sites. |
View CCR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against Myeloperoxidase (MPO) | High-purity EPX recombinant protein enables rigorous cross-reactivity and selectivity screening against homologous peroxidases. |
| Native Glycosylation & Folding | HEK293 mammalian expression host ensures correct post-translational modifications and conformational integrity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives in Small Molecule Screening | Sequence-verified EPX proteins and validated siRNA transfection controls minimize off-target validation errors. |
Live EPX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
Eosinophil Peroxidase (EPX) is a major granular protein secreted by activated eosinophils, playing a central role in the pathogenesis of asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). The race for EPX therapeutics is intensifying, with major players shifting focus from traditional systemic anti-eosinophil mAbs (such as anti-IL-5) to direct, localized EPX inhibition. As first-generation therapies reach the clinic, the next wave of R&andD is targeting highly selective small-molecule inhibitors and neutralizing antibodies to prevent EPX-mediated tissue damage without compromising systemic immune surveillance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Pharmaceutical Developers | Asthma, COPD, EoE | Enzymatic Selectivity Assay (Need high-purity, active EPX vs MPO) |
| Monoclonal Antibodies | Biotech Consortia | Severe Asthma, Inflammatory Bowel Disease | Epitope Mapping & Binding Affinity (Need HEK293-expressed EPX) |
| RNA Therapeutics | Academic & Clinical Spin-offs | Eosinophilic Disorders | In Vitro Knockdown Validation (Need sequence-verified EPX siRNA) |